Milrinona Administration for Cerebral Vasospasm

Safety Considerations

• The American Heart Association recommends caution when administering milrinona due to its vasodilatory properties, which can cause systemic hypotension, the most common adverse effect 1
• Close hemodynamic monitoring is essential during administration, and if hypotension occurs, it can be reversed with titrated boluses of isotonic crystalloids or colloids 2
• Hypotension-related toxicity can be overcome by initiating norepinephrine or vasopressin 2

Mechanism and Advantages

• The European Society of Cardiology notes that milrinona acts as a phosphodiesterase type III inhibitor, dilating vessels through a mechanism similar to papaverine, and its effectiveness is maintained even with downregulation of beta-adrenergic receptors 3, 4

Important Warnings

• The European Heart Association advises against administering rapid loading doses in hypotensive patients, and recommends initiating without a loading bolus in patients with systolic blood pressure < 100 mmHg 3, 4
• Milrinona should be discontinued at the first sign of arrhythmia or hypotension caused by excessive decrease in systemic vascular resistance 2
• The prolonged elimination half-life (1-10 hours depending on organ function) means it can take 3-30 hours to reach 90% of steady state without a loading dose 2

Milrinone Dosing for Cerebral Vasospasm

Intravenous Administration

• The European Heart Journal recommends omitting the loading dose of milrinone if systolic blood pressure is less than 100 mmHg to avoid severe hypotension 5
• For patients with renal impairment, the European Heart Journal suggests reducing infusion rates based on creatinine clearance, with a rate of 0.38 mcg/kg/min for CrCl 40 mL/min 5

Critical Monitoring and Safety Considerations

• The Stroke journal notes that milrinone has a lower risk of elevated intracranial pressure compared to papaverine, and is preferred for its more durable angiographic response and better safety profile 6
• The Stroke journal also recommends monitoring intracranial pressure closely during intra-arterial administration of milrinone 6

Common Pitfall to Avoid

• The European Heart Journal warns against administering the loading dose of milrinone to hypotensive patients, and recommends beginning with maintenance infusion only and providing concurrent vasopressor support if SBP is less than 100 mmHg 5